Previous 10 | Next 10 |
2024-03-25 13:07:32 ET Summary M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot ...
Analysis from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF <50% in over 1500 patients, strengthening the safety profile of CAMZYOS ® (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy Real-world data rea...
2024-03-25 02:07:51 ET Summary Sanofi has underperformed the U.S. stock market lately but now offers one of the smartest growth-at-a-reasonable-price setups in Big Pharma. Sanofi is best known for its patented drug Dupixent and numerous vaccines manufactured for global use, which ...
2024-03-23 07:52:56 ET Summary PureTech Health's founded entity, Karuna Therapeutics, has been successful in developing a therapeutic with an optimized profile. Karuna Therapeutics was acquired by BMY for $14 billion. PureTech's lead asset, LYT-100, may be a promising treatmen...
2024-03-21 13:21:53 ET More on China and the US Tim Cook visits China again, meet with suppliers as sales pressure continues China responds to TikTok ban: 'This will inevitably backfire on the U.S.' Why We Avoid Direct Investments in China Read the full art...
2024-03-20 17:53:04 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb Is Not A Buy For Me Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript) Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Pa...
Abecma demonstrated superiority over standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile with mostly low-grade and transient occurrences of cytokine release syndrome and neurotoxicity App...
2024-03-20 09:00:32 ET More on Labcorp Laboratory Corporation of America Holdings (LH) Q4 2023 Earnings Call Transcript Laboratory Corporation of America Holdings 2023 Q4 - Results - Earnings Call Presentation Labcorp introduces weight loss management portfolio ...
2024-03-20 07:28:13 ET More on Bristol-Myers Squibb Bristol-Myers Squibb Is Not A Buy For Me Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript) Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners G...
Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in overall survival compared to investigator’s choice of sorafenib or lenvatinib Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -9DW trial evaluatin...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...